Can You Keep Your Honeymoon Going? SAB Bio’s Clinical Trial for Newly Diagnosed Type 1 Patients
A new investigational medicine called SAB-142 is designed to help reduce or prevent loss of cells that produce insulin in the body. SAB Biotherapeutics is running the SAFEGUARD clinical study testing SAB-142 in people newly diagnosed with type 1 diabetes to see if it can prevent disease progression. In this episode of Think Like a Pancreas—The Podcast, host Gary Scheiner sits down with SAB Biotherapeutics CEO, Sam Reich to discuss what this study means for people with stage 3 type 1 diabetes, who can enroll, and why studies like these are so important. MEET YOUR HOST AND HIS GUEST: Gary Scheiner, MS, CDCES is the owner and Clinical Director of Integrated Diabetes Services. He is an award-winning Certified Diabetes Educator, Masters-level Exercise Physiologist and person with type-1 diabetes since 1985. Gary is also actively involved with many diabetes related organizations as a volunteer and clinical advisor. Sam Reich is the Chief Executive Officer of SAB Biotherapeutics. Mr. Reich holds a Bachelor of Arts degree with High Honors in Biochemistry from Clark University, cum laude, Phi Beta Kappa, where he received the Margaret Comer award, presented to the top graduating student in the Biological Sciences. He later attended the University of Pennsylvania where he was a Doctoral Candidate in the lab of Jean Bennett. He left prior to defending his thesis to found Acuity Pharmaceuticals, Inc., receiving a Master of Science. He is listed as an inventor on 14 U.S. patents and more than 50 worldwide patents related to the first uses of siRNA as therapeutics. SPONSORED BY: SAB Bio is a clinical-stage biopharmaceutical company focused on advancing research for people living with type 1 diabetes. Its mission is to dramatically redefine what it means to be diagnosed with type 1 diabetes by developing a medicine to change the course of disease, not just treat symptoms. A new investigational medicine called SAB-142 is designed to help reduce or prevent loss of cells that produce insulin in the body. The SAFEGUARD clinical study is testing SAB-142 in people newly diagnosed with type 1 diabetes to see if it can prevent disease progression. People between 5 and 17 years old may qualify to participate. Learn more about the SAFEGUARD clinical study at SafeguardStudy.com or call 1-844-763-1890 KEY TAKEAWAYS AND HIGHLIGHTS: ✔️Preserving beta cell functioning can make diabetes management much easier for people living with type 1 diabetes. ✔️Taking part in clinical studies not only helps research move forward but also allows you to take your place in history. CHAPTERS: 00:00 Welcome 01:44 Meet Sam Reich 03:11 SAB = Saving All Beta Cells? 03:54 Plainly Speaking, What is SAB-142? 06:28 How does SAB-142 Differ from other drugs on the market? 08:30 The SafeGuard Study 13:52 Eligible Candidates for the SafeGuard Study 15:05 What’s it in for you to Participate? 17:03 Prise Study 19:08 Debunking the Cure Conspiracy 22:12 When Can We Start Using SAB 142? RESOURCES: SafeguardStudy.com or call 1-844-763-1890 From Crisis to Control. How T1D Screening Saves Lives https://Integrateddiabetesservices.podbean.com/e/how-t1d-screening-saves-lives/ https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3-type-1-diabetes/ CONNECT WITH US: 🔵Website: integrateddiabetes.com 🔵 Follow on Social Media: @integrated_diabetes_services and @ integrateddiabetesservices on Facebook 🔵To work with the Integrated Diabetes Services Team , visit https://integrateddiabetes.com/appointments/ or email info@integrateddiabetes.com SUBSCRIBE AND REVIEW: If the podcast has helped you to live better with diabetes, please tell someone else how to find it! If you have a question, take a moment and ask! We reply to everyone. And then be sure to subscribe on Apple Podcasts, Spotify, or your favorite podcast platform to ensure that you never miss an episode! Disclaimer The information contained in this program is based on the experience and opinions of the Integrated Diabetes Services clinical team. Please discuss any changes to your treatment plan with your personal healthcare provider before implementing.




